T. Katsunuma et al., GLUCOCORTICOIDS REDUCE TACHYKININ NK2 RECEPTOR EXPRESSION IN BOVINE TRACHEAL SMOOTH-MUSCLE, European journal of pharmacology, 344(1), 1998, pp. 99-106
Neurokinin A is not only a potent bronchoconstrictor, but also has imm
uno-modulatory effects in animals and man, mediated via tachykinin NK2
receptors. We have examined the effect of the glucocorticoid, dexamet
hasone, on tachykinin NK2 receptor mRNA and the number of tachykinin N
K2 receptors in bovine tracheal smooth muscle in vitro by Northern blo
t analysis using a human tachykinin NK2 receptor cDNA probe and recept
or binding assay using [H-3]SR48968 tylamino-4-phenylpiperidino-2-(3,4
-dichlorophenyl) butyl]benzamide). Tachykinin NK2 receptor mRNA showed
a time-dependent suppression (62% reduction after 6 h at 10(-7) M of
dexamethasone), as well as a concentration-dependent suppression after
the incubation with dexamethasone (IC50 = 1.3 x 10(-8) M). This suppr
ession was abolished by the glucocorticoid receptor antagonist, mifepr
istone (RU38486), indicating that dexamethasone acts via the glucocort
icoid receptor. It was also abolished by the protein synthesis inhibit
or, cycloheximide (10 mu g/ml), indicating that new protein synthesis
is required on this suppression. Using the RNA polymerase inhibitor ac
tinomycin D (5 mu g/ml), we showed that the stability of tachykinin NK
2 receptor mRNA was not affected by dexamethasone (t(1/2) = 5 h). Nucl
ear run-on assays revealed a 51% reduction in the rate of tachykinin N
K2 receptor gene transcription after treatment with dexamethasone for
6 h. Radioligand binding assay using an selective tachykinin NK2 recep
tor antagonist, [H-3]SR48968 showed a significant decrease in the numb
er of receptor binding sites after 16 h (B-max = 262 +/- 23 versus 213
+/- 13 fmol/mg protein for vehicle and dexamethasone treatment respec
tively, P < 0.05), with no significant change at the earlier time poin
ts. These results suggest that glucocorticoids act on glucocorticoid r
eceptors to decrease tachykinin NK2 receptor expression by decreasing
the rate of tachykinin NK2, receptor gene transcription. (C) 1998 Else
vier Science B.V.